MelliCell

Melli Cell

Biotechnology, Watertown Ma Us, Newton, Massachusetts, 02472, United States, 1-10 Employees

mellicell.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: +16*********

Who is MELLICELL

MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of the...

Read More

map
  • Watertown Ma 02472 Us, Newton, Massachusetts, 02472, United States Headquarters: Watertown Ma 02472 Us, Newton, Massachusetts, 02472, United States
  • 2020 Date Founded: 2020
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from MELLICELL

MelliCell Org Chart and Mapping

Employees

Aaron Glieberman

Director of Platform Development

Ben Pope

Chief Scientific Officer and Co-Founder

Monica Ly

Junior Staff Accountant

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding MelliCell

Answer: MelliCell's headquarters are located at Watertown Ma Us, Newton, Massachusetts, 02472, United States

Answer: MelliCell's phone number is +16*********

Answer: MelliCell's official website is https://mellicell.com

Answer: MelliCell's revenue is $1 Million to $5 Million

Answer: MelliCell has 1-10 employees

Answer: MelliCell is in Biotechnology

Answer: MelliCell contact info: Phone number: +16********* Website: https://mellicell.com

Answer: MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts diabetes better than obesity per se. The products we develop will treat obesity and diabetes by shrinking fat cell size and by preventing compromised metabolism in enlarged cells. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access